Seres Therapeutics (MCRB) Return on Sales (2016 - 2026)

Seres Therapeutics (MCRB) posted Return on Sales of 0.71% for Q1 2026, down 7452.63% sequentially from 0.01% in Q3 2024.

Seres Therapeutics (MCRB) Return on Sales (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported Return on Sales for 10 years, with the latest figure at 0.71% in Q1 2026.

Quarterly Return on Sales changed N/A year-over-year to 0.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.22% (changed N/A YoY) and the FY2022 annual result came in at 0.09%, down 7.0% from the prior year.
Return on Sales retreated to 0.71% in Q1 2026 per MCRB's latest filing, from 0.01% in the prior quarter.
Over five years, Return on Sales peaked at 0.46% in Q1 2024 and troughed at 47.83% in Q3 2022.
A 4-year average of 4.86% and a median of 0.3% in 2023 frame the typical range for Return on Sales.
The sharpest annual moves came in 2022 and 2023: Return on Sales slumped 4627 bps in 2022, then surged 4761 bps in 2023.
Over 4 years, Return on Sales stood at 0.62% in 2022, then soared by 100 bps to 0.0% in 2023, then slumped by 1928 bps to 0.01% in 2024, then sank by 7453 bps to 0.71% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.71%, 0.01%, and 0.0% for Q1 2026, Q3 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.03 Bn	131.18 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.64 Bn	77.64 Bn	3.93 Bn	0.00%
3	Argenx Se	64.93 Bn	59.75 Bn	1.37 Bn	0.00%
4	Moderna	57.93 Bn	52.80 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.95 Bn	36.86 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.00 Bn	9.60 Bn	668.28 Mn	0.00%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	0.00%
10	Seres Therapeutics	43.87 Mn	43.87 Mn	-	-0.29%

Download Data